Biomerica (NASDAQ:BMRA) issued its quarterly earnings results on Wednesday. The company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.03), Fidelity Earnings reports. Biomerica had a negative net margin of 52.42% and a negative return on equity of 40.08%.
NASDAQ BMRA traded down $0.27 on Friday, reaching $5.79. The company had a trading volume of 3,646 shares, compared to its average volume of 1,687,348. Biomerica has a 52 week low of $2.05 and a 52 week high of $23.39. The stock’s 50 day moving average is $5.75 and its 200-day moving average is $7.05. The stock has a market cap of $68.05 million, a price-to-earnings ratio of -17.66 and a beta of -0.47.
In related news, Director Catherine Coste bought 9,100 shares of Biomerica stock in a transaction on Monday, October 26th. The shares were purchased at an average price of $5.45 per share, for a total transaction of $49,595.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 23.70% of the company’s stock.
A number of research analysts have commented on BMRA shares. B. Riley decreased their price objective on Biomerica from $11.00 to $10.00 and set a “buy” rating on the stock in a research report on Tuesday. Aegis decreased their price target on Biomerica from $13.00 to $11.00 and set a “buy” rating on the stock in a report on Monday, October 19th. Finally, Colliers Securities initiated coverage on shares of Biomerica in a research note on Tuesday, November 10th. They issued a “buy” rating and a $13.00 target price on the stock.
Biomerica, Inc, a biomedical technology company, together with its subsidiaries, develops, patents, manufactures, and markets diagnostic and therapeutic products or detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, or fecal specimens from patients in the diagnosis of various diseases and other medical complications; or to measure the level of specific bacteria, hormones, antibodies, antigens, or other substances, which exist in the patient's body and stools or blood in extremely small concentrations.
Read More: Market Capitalization
Receive News & Ratings for Biomerica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biomerica and related companies with MarketBeat.com's FREE daily email newsletter.